人非小细胞肺癌细胞中端粒酶活性的检测与研究

目的 研究非小细胞肺癌细胞癌组织中端粒酶活性表达,探讨端粒酶生表达与非小细胞肺癌发生发展的关系。方法 收集经手术及病理证实的非小细胞肺癌４８例标本,１２例肺癌癌旁肺组织、７例非肿瘤病例所取正常肺组织作对照。用端粒酶检测试剂盒检测组织本端粒酶活性。结果 ７５．００％（３６／４８）非小细胞肺癌组织标本检出端粒酶活性,８．３３％（１／１２）癌旁肺组织检出端粒酶活笥,７例非肿瘤标本所取的正常肺组织均未检出     

食管癌及癌旁组织中端粒酶活性检测及其意义

目的探讨食管癌及癌旁组织中端粒酶活性检测的意义. 方法采用 PCR技术为基础的 TRAP法检测了 39例食管癌及癌旁组织端粒酶活性. 结果 39例食管癌组织中 34例端粒酶活性阳性,阳性率为87.2%,癌旁组织中3例阳性,阳性率为7.7%,9例食管良性组织中1例阳性,阳性率为11.1%.食管癌与相应癌旁组织和良性食管组织端粒酶阳性检测率相比,差异有显著性意义(p<0. 01).伴有淋巴结转移的 25例食管癌端粒酶阳性检测率为96.0%,显著高于未伴有淋巴结转移的阳性率(71.4%),两者差异有显著性意义(p<0.05). 结论端粒酶激活与食管癌发生发展有关,对端粒酶活性进行检测对食管癌的诊断和判断预后有重要价值.     

食管癌及癌旁组织中端粒酶活性检测及其意义

目的探讨食管癌及癌旁组织中端粒酶活性检测的意义.方法采用PCR技术为基础的TRAP法检测了39例食管癌及癌旁组织端粒酶活性.结果39例食管癌组织中34例端粒酶活性阳性,阳性率为87.2%,癌旁组织中3例阳性,阳性率为7.7%,9例食管良性组织中1例阳性,阳性率为11.1%.食管癌与相应癌旁组织和良性食管组织端粒酶阳性检测率相比,差异有显著性意义(p<0.01).伴有淋巴结转移的25例食管癌端粒酶阳性检测率为96.0%,显著高于未伴有淋巴结转移的阳性率(71.4%),两者差异有显著性意义(p<0.05).结论端粒酶激活与食管癌发生发展有关,对端粒酶活性进行检测对食管癌的诊断和判断预后有重要价值.     

乳癌组织端粒酶活性表达及其与p16基因的关系

目的：探讨乳房恶性肿瘤组织中端粒酶活性的表达情况及ｐ１６抑癌基因的影响。方法：应用端粒重复放大程序－酶标法（ＴＲＡＰ－ＥＬＩＳＡ）及ＴＲＡＰ－银染法检测３５例有乳癌组织及２４例良性肿瘤组织中的端粒酶活性,并采用多重ＰＣＲ技术对乳癌组织的ｐ１６基因的缺失空谈进行了分析,结果：３５例乳癌标本中有２８例端粒酶活性表达为阳性（８０％）,而２４例乳房良性肿瘤标本中仅１例端粒酶活性表达阳性（４．１％）。此外３５例乳癌标本中的１５例存在有ｐ１６基因的外显子２及外显子１的缺失（４２．８％）,而该１５例中有１４例被检测为端粒酶活性阳性（９３．３％）,但２０例未缺失标本的端粒酶阳怀率仅为７０％（１４／２０）。结论：端粒酶活性与乳房肿瘤组织的恶性程度密切相关,提示端粒酶参与了肿瘤的形成过程,而端粒酶活性的增高与ｐ１６抑癌基因的缺失突     

端粒酶基因在人肿瘤组织中的表达

目的 探讨端粒酶基因表达与肿瘤恶性表型及其与端粒酶活性的关系;评价端粒酶基因表达检测在肿瘤诊断中的价值。方法 用原位杂交的方法检测端粒酶基因ｈＴＲ和ｈＴＲＴ在７８例人觉癌组织,２０例癌前病变,２８例良性病变中的表达及分布情况。结果 ７８例癌中ｈＴＲ阳性率为８５％（６６／７８）,ｈＴＲＴ阳性率为８２％（６４／７８）;在癌旁组织中ｈＴＲ、ｈＴＲＴ的表达阳性率分别为３％（２／７８）、５％（４／７８）;２     

喉癌/下咽癌端粒酶活性表达的初步研究

目的 :通过对喉癌 /下咽癌、癌旁组织和慢性炎症粘膜及喉乳头状瘤和喉部炎性息肉标本进行端粒酶活性检测 ,探讨端粒酶在喉癌 /下咽癌发病机制中的重要作用。对端粒酶活性检测为喉或下咽部肿物的诊断和鉴别诊断提供新的指标和理论依据。方法 :采用非放射性端粒重复序列扩增法 (TRAP)。结果 :1喉癌 /下咽癌端粒酶阳性率为91.7% (2 2 / 2 4) ,2 4例手术切缘正常组织和 17例喉癌炎性息肉组织未检测到端粒酶活性。2癌旁组织端粒酶阳性率为16 .7% (4/ 2 4) ,经过复阅 HE染色切片 ,其中有 2例发现散在的癌细胞浸润 ,而许多肿瘤细胞的微小病灶是…     

膀胱癌及其癌旁组织中ras—P^21蛋白的表达

应用免疫组织化学技术（ＡＢＣ法）对４２例膀胱癌及癌旁组织中ｒａｓ癌基因产物Ｐ＾２１蛋白检测结果表明：癌组织中Ｐ＾２１阳性率和癌旁组织中阳性主经分别是７３．８％，１４．３％。Ｐ＾２１蛋白的阳性率随着病理分级、肿瘤分期的上升其阳性度增强，在癌旁组织中Ｐ＾２１阳性者其预后更差。     

肝细胞癌及癌旁肝组织中bcl—2和p53蛋白表达与？…

目的：探讨ｂｃｌ－２和ｐ５３蛋白的表达与端粒酶活性的相关性及其与ＨＣＣ发生的关系。方法：利用端粒酶原位标记法显示端粒酶活性,采用Ｓ－Ｐ法免疫组化技术的检测ｂｃｌ－２和ｐ５３蛋白。结果：端粒酶在ＨＣＣ中的阳性率（９１．７％）显著高于癌旁肝组织（５８．３％）（Ｐ〈０．０５）,端粒酶活性强度与ＨＣＣ分化程度无关（Ｐ〉０．０５）;癌组织中ｂｃｌ－２和ｐ５３蛋白的阳性率均高于癌旁组织（Ｐ〈０．０１）;ＨＣＣ     

卵巢肿瘤组织中端粒酶活性的表达

目的分析端粒酶活性在卵巢肿瘤中的表达,探讨端粒酶活性作为卵巢肿瘤诊断肿瘤标记物的意义。方法取冰冻肿瘤组织,采用端粒重复序列扩增法（Telomeric Repeat Amplication Protocol）,结合银染,共测定了27例卵巢癌、5例良性卵巢肿瘤、22例卵巢癌癌旁组织以及12例正常卵巢组织中端粒酶活性,并分析其与组织分级、FIGO分期、病理类型以及有无转移的关系。PCR产物以采用聚丙烯酰胺凝胶电泳分析,以出现特征性的6-bp间隔的特征性阶梯状条带为阳性。出现〉100bp的条带为强阳性,出现〈99bp的条带为中低阳性。结果本实验共对66份标本进行了检测,12例正常卵巢组织中,仅有2例表达端粒酶活性;5例卵巢良性肿瘤中,1例表达端粒酶弱阳性。27例卵巢恶性肿瘤标本中,有23例表达端粒酶活性（其中强阳性16例）;在检测的22例卵巢上皮癌的癌旁组织中,有12例表达端粒酶弱阳性。卵巢恶性肿瘤的端粒酶活性表达阳性率显著高于卵巢良性肿瘤（P=0.0090）和正常卵巢（P=0.0000）。Ⅰ-Ⅱ期患者端粒酶活性阳性率71%,Ⅲ-Ⅳ期患者端粒酶活性阳性率90%（P=0.269）。而强阳性率Ⅲ-Ⅳ期明显高于Ⅰ-Ⅱ期（P=0.009）。在肿瘤类型和组织学分级中,端粒酶阳性表达率均没有显著差异。结论在卵巢恶性肿瘤组织中端粒酶活性有较高的表达率;早期和晚期卵巢肿瘤组织中端粒酶活性阳性率没有明显差异,但晚期卵巢肿瘤组织中的端粒酶活性程度较高;端粒酶活性有可能作为早期诊断卵巢肿瘤的标记物之一,并可以作为卵巢肿瘤判断预后的指标。     

Clinical implications of telomerase activity in resected hepatocellular carcinoma.

This study investigated the relationship of telomerase activity to its clinical implications in hepatocellular carcinoma (HCC). Telomerase activity was quantatively examined by a non-radioisotope quantitative system based on a TRAP-eze (ONCOR) in 42 HCC nodules and 40 non-cancerous liver tissue adjacent to the HCC nodules, obtained by surgical resection. Telomerase activity was confirmed in 37 HCC nodules (88.1%), being more statistically intense in de-differentiated tumors (p<0.01). Telomerase activity was positive in 9 cases (22.5%) of non-cancerous liver tissue and its activation was closely associated with the biologically malignant potential of the tumor itself such as the histological grade, portal vascular invasion, and intrahepatic metastasis (p<0. 05). The disease-free survival rate with its activity was also statistically lower than that without its activity of the non-cancerous tissue (p<0.01). These results indicate that telomerase may be a useful marker of biological characteristics in HCC and may lead to more effective surgical procedures.     

胃癌组织中端粒酶检测的相关性研究

目的 :探讨端粒酶与胃癌的关系。方法 :分别对胃癌手术患者取胃癌组织、癌旁组织和正常胃粘膜组织 ,用PCR -ELISA法检测端粒酶活性。结果 :胃癌组织端粒酶阳性率高于癌旁组织和正常胃粘膜组织 (P<0 0 1)。结论 :活化的端粒酶在胃癌的发生、发展过程中起了促进作用 ,同时端粒酶的检测对胃癌诊断具有一定的临床价值。     

原发性肝癌及慢性肝脏病变端粒酶活性的研究

目的比较原发性肝细胞癌（ＨＣＣ）及其癌旁不同慢性病变组织端粒酶活性的异同,探讨端粒酶活性在恶性肿瘤诊断中的意义。方法用ＴＲＡＰ方法检测３８例ＨＣＣ及其癌旁不同慢性病变肝组织的端粒酶活性。同时以４例正常肝组织为对照。结果３８例ＨＣＣ中３２例显示端粒酶活性（８６８％）。端粒酶活性与ＨＣＣ的细胞分化、类型、大小及有无乙型肝炎病毒（ＨＢＶ）感染无关,但与病人血清中甲胎蛋白（ＡＦＰ）水平相关。端粒酶活性阴性组ＡＦＰ水平明显低于各阳性组（Ｐ＜００１）。正常肝（４例）、先天性胆管闭锁（４例）、肝小叶间纤维增生（２例）、慢性病毒性肝炎（２例）及未见明显病变肝组织（７例）均未见有端粒酶活性。２５例肝硬化中４例端粒酶呈弱活性。结论端粒酶活性见于大多数ＨＣＣ及个别肝硬化组织,其活性可能在ＨＣＣ的发生、发展中起重要作用,有希望成为恶性肿瘤诊断的标记物。     

肝癌组织中ras,c—myc,c—erbB—2和p53的蛋白表达

目的：探讨肝癌的发病机理，方法：应用免疫组化ＳＰ法对４６例肝癌细胞组织及其３８列癌旁中癌基因ｒａｓ，ｃ－ｍｙｃ，ｃ－ｅｒｂＢ－２和抑癌基因ｐ５３基蛋白达作定位研究，结果：在癌组织中的检出率分别为５８．７％，６７．４％，４７．８％和２０．４％，癌旁组织中的检出率分别为３４．２％，４７．４％，４２．１％和７．９％，ｒａｓｐ２１蛋白位于肝细胞和肝细胞的胞浆内ｃ－ｅｒｂＢ－２蛋白位于肝细胞和肝癌细胞的胞浆     

In situ detection of telomerase enzymatic activity in human hepatocellular carcinogenesis

Telomerase enzymatic activity has been detected in most human malignant tumours including hepatocellular carcinoma. In order to assess the cellular source, the topographic distribution, and the chronology of telomerase re-expression during human liver carcinogenesis, an in situ technique derived from the standard TRAP (telomeric repeat amplification protocol) assay was set up that allowed the detection of telomerase enzyme activity at the cellular level on frozen liver tissue sections. In situ TRAP (ISTRAP) was performed on 27 hepatocellular carcinomas (HCCs) and 57 non-tumour livers, including normal liver without HCC, liver samples adjacent to tumour with and without hepatic cirrhosis, and biopsies of chronic hepatitis. In HCC, telomerase was detected in the nuclei of liver tumour cells in 23/27 cases (85%), with a heterogeneous distribution within the tumour. This signal was also detected in clusters of hepatocytes in 16/26 (61%) samples of liver adjacent to HCC, in 10/23 (43%) cases of chronic viral hepatitis without adjacent HCC, and in scattered nuclei of 2/8 histologically normal livers. Comparison of the results obtained with ISTRAP and standard TRAP assays on tissue extracts suggests a gain in sensitivity with the in situ technique. This study confirms that telomerase is expressed in most HCCs and suggests that focal telomerase reactivation is an early event during human liver carcinogenesis. ISTRAP is a sensitive technique that allows the study of telomerase expression in the morphological context.     

EZH2在肝细胞癌中的表达及临床意义

目的 探讨EZH2在肝细胞癌中的表达及临床意义方法采用RT-PCR、免疫组织化学和Western blotting方法分析肝癌及癌旁组织EZH2mRNA转录和蛋白表达水平及其与临床病理因素的关系.结果 在42例肝癌组织中检出26例EZH2mRNA,而在相应的42例癌旁组织中只检出12例,癌组织EZH2mRNA阳性率高于...     

肝细胞癌组织中端粒酶逆转录酶基因hTERT的表达不依赖PCNA和P53

目的 :研究肝细胞癌 (HCC)中端粒酶逆转录酶基因hTERT的表达及其与增殖细胞核抗原 (PCNA)和P5 3基因的关系 ,探讨其在HCC发生、发展及预后复发中的意义。方法 :采用免疫组化染色法检测 4 2例HCC组织中hTERT、增殖细胞核抗原(PCNA)和P5 3蛋白的表达 ,并对hTERT与HCC的临床病理特征以及PCNA、P5 3蛋白表达的关系进行分析。结果 :HCC中hTERT、PCNA和P5 3蛋白的阳性率 ,分别为 71.4 % (30 / 4 2 )、76 .2 % (32 / 4 2 )、73.8% (31/ 4 2 ) ;而hTERT在正常肝脏组织中不表达。hTERT在Ⅰ、Ⅱ和Ⅲ级HCC组织中的表达率 ,分别为 4 0 .0 % (4 / 10 )、70 .0 % (14 / 2 0 )及 10 0 % (12 / 12 )。HTERT的表达率与疾病复发有显著相关性 (P <0 .0 5 )。结论 :hTERT表达的异常可能与肝癌的发生、发展有关。hTERT与PCNA和P5 3无明显的相关性。检测hTERT的表达可作为预测肝癌预后复发的潜在指标 ,并提示HCC为由多基因参与的疾病     

Localization of hepatitis B surface antigen in hepatocellular carcinoma

The author respectively examined the localization of hepatitis B surface antigen (HBsAg) in 150 autopsy cases of hepatocellular carcinoma (HCC) with particular attention to growth pattern of HCC. Varying numbers of orcein-positive cells were observed in 42 cases (28.0%) with various distribution patterns, and all the 42 cases were confirmed with immunoperoxidase technique for HBsAg. HBsAg-positive cells were detected in HCC tissue in 10 cases (6.6%) among the 150 cases. Regarding the growth pattern of HCC in the 10 cases, many HBsAg-positive cells were seen in HCCs of the sinusoidal and replacing types, in which the hepatocytes were frequently retained in the cancerous tissue, particularly around the tumor-nontumor boundary. On the other hand, there was no HBsAg-positive cell in the encapsulated type HCC which was the most common (approximately 50%) in the present study and in which the retained hepatocytes were hardly seen. Meticulous histological observation after decoloration of the positive reaction to HBsAg in the sections treated with immunoperoxidase technique and subsequent eosin stain disclosed that HBsAg-positive cells in HCC tissue were retained hepatocytes in 9 cases, and the possibility of HCC cell was not denied in one case. Moreover, HBsAg-positive cells were never detected in tumor thrombi of the portal vein branches and pulmonary metastases.